Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
6,741 total articles
Stereotaxis announced its Q1 2026 financial results, highlighting FDA approvals for its MAGiC catheter and Synchrony digital OR system, ongoing commercial rollout, and a transformational acquisition of Robocath to enhance its robotic endovascular platform. While Q1 revenue declined slightly due to transition from legacy products, the company expect…
Robinhood Markets, Inc. announced that its Chief Brokerage Officer will present at the J.P. Morgan Global Technology, Media and Communications Conference on May 19, 2026. The presentation will be webcast live and available for replay, providing insights into the company's business and strategy. This participation offers transparency and engagement …
Atea Pharmaceuticals reported Q1 2026 financial results and provided updates on its antiviral drug development programs. The company is progressing two pivotal Phase 3 trials for its oral HCV regimen bemnifosbuvir/ruzasvir with topline results expected mid and late 2026, respectively. Encouraging preclinical data support the advancement of AT-587, …
Elevra Lithium Limited has purchased and terminated the discounted life-of-mine spodumene concentrate offtake agreement previously held by Waratah Capital Advisors for the Moblan Lithium Project, increasing its control to 100% of the project's lithium concentrate output. The transaction was equity-based, preserving cash, and is expected to strength…
Rezolute, Inc. announced Q3 fiscal 2026 financial results and provided a business update, highlighting significant clinical benefits in their Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism (HI). The data demonstrated clinically relevant and nominally statistically significant reductions in hypoglycemia and improvements in glycemi…
Digital Realty, a leading global data center platform company, declared quarterly cash dividends for its common stock and four series of cumulative redeemable preferred stock for Q2 2026. Dividends will be paid on June 30, 2026, to shareholders of record on June 15, 2026.
Pharvaris reports Q1 2026 financial results, confirms on-track NDA submission for deucrictibant IR in HAE treatment, and anticipates pivotal Phase 3 CHAPTER-3 study topline data by Q3 2026. Enrollment continues in pivotal studies targeting hereditary and acquired angioedema. Successful $132 million offering enhances cash runway into 2028, supportin…
Biomea Fusion, a clinical-stage company specializing in diabetes and obesity treatments, announced its management's planned participation in upcoming investor conferences in New York. The company will present updates on its oral small molecule therapies targeting metabolic disorders, including icovamenib and BMF-650. Webcasts of the sessions will b…
Red Cat Holdings, a U.S.-based defense and national security drone and robotic solutions provider, has announced a proposed underwritten public offering of $200 million in common stock with an option for underwriters to purchase an additional $30 million. The proceeds will be used for general corporate purposes including acquisitions, R&D, capital …
Nyxoah SA announced its Q1 2026 financial results highlighted by a robust 25% sequential growth in U.S. net revenue owing to the strong commercial launch of its Genio hypoglossal neurostimulation system for obstructive sleep apnea (OSA). The company continues to gain surgeon trainees and account activations, alongside achieving 100% prior authoriza…
Neumora Therapeutics, a clinical-stage biopharmaceutical company focusing on novel neuroscience drug development, announced it will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The event will be webcast live and archived for up to 30 days.
Espey Mfg. & Electronics Corp. reported third quarter fiscal 2026 results showing higher net income and earnings per share compared to the prior year quarter despite a slight decline in nine-month sales and new orders. The company highlights strong backlog and a focus on margin expansion through favorable product mix, operational leverage, and cost…
Lifecore Biomedical, a US-based injectable CDMO, announced its participation in the CDMO Live Europe conference held in Rotterdam. The company will engage in panel discussions and meetings to present its capabilities in sterile injectable pharmaceutical product development and manufacturing, focusing on process development and manufacturing service…
Fractyl Health announced its first quarter 2026 financial results and provided updates on its lead metabolic therapeutics programs: Revita, a procedural therapy for post-GLP-1 weight maintenance, and Rejuva, a gene therapy platform targeting type 2 diabetes. The company remains on track for key 2026 clinical data readouts, including pivotal REMAIN-…
Sana Biotechnology announced preclinical data showing its in vivo CAR T cell therapy candidate SG293 achieves targeted and potent CAR T cell generation and effective B cell depletion in non-human primates without lymphodepleting chemotherapy. The data supports advancing SG293 into clinical trials for non-Hodgkin lymphoma later this year and SG227 f…
CNB Financial Corporation announced a quarterly cash dividend of $0.19 per share payable on June 15, 2026, to shareholders of record as of June 1, 2026. The company operates primarily through its subsidiary CNB Bank, which offers comprehensive banking services across multiple states including Pennsylvania, Ohio, New York, and Virginia.
Capricor Therapeutics reports first quarter 2026 financial results with a net loss of $33.9 million and a cash balance of approximately $279 million, supporting operations into Q4 2027. The company's Biologics License Application (BLA) for Deramiocel, a potential treatment for Duchenne muscular dystrophy (DMD), is under active FDA review with a PDU…
Lumexa Imaging announced the addition of four new outpatient imaging centers in four U.S. locations as part of its multi-channel growth strategy, including acquisitions with joint venture partners Advocate Health and UPMC. The company now operates over 190 outpatient centers nationwide and plans to continue expansion through de novo developments, a…
GrowGeneration Corp. announced its first quarter 2026 financial results, reporting a 7.5% year-over-year increase in net sales to $38.4 million, along with a significant improvement in net loss by $4.5 million to $4.9 million. The company experienced increased proprietary brand penetration to 37% of cultivation and gardening revenue and improved ad…
PEDEVCO Corp., a publicly traded energy company specializing in oil and gas asset acquisition and development in the Rocky Mountain region, announced its participation in the LD Micro Invitational XVI Conference. The management team will present and engage with investors during the event held from May 17-19, 2026 in Los Angeles. The conference serv…
XBP Global Holdings, Inc. has scheduled a conference call and webcast for May 14, 2026, to discuss its first quarter 2026 financial results. The company, a multinational technology and services provider specializing in hyper-automation and digital transformation, will issue a press release after market close on the same day. Management will host th…
Nurix Therapeutics announced that updated efficacy and safety data from their ongoing Phase 1a/b trial of the BTK degrader bexobrutideg (NX-5948) in chronic lymphocytic leukemia patients will be presented orally at the 31st Congress of the European Hematology Association. The drug is currently being evaluated in pivotal Phase 2 and Phase 1a/b clini…
Surrozen, Inc., a biotechnology company specializing in targeted Wnt signaling therapeutics for ophthalmic diseases, announced that its management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The presentation will be available via webcast and will outline the company's research, development plans, a…
Hour Loop, Inc., a U.S.-based online retailer, announced its Q1 2026 financial results showing a 16% year-over-year increase in net revenues to $29.9 million, with net income rising to $0.82 million. The company attributed revenue growth to expanded inventory availability and strong sales execution, despite a modest decline in gross margin due to h…
Bolt Biotherapeutics, a clinical-stage biopharmaceutical company focused on innovative cancer immunotherapies, reported its Q1 2026 financial results and business update. The company is advancing its lead product BDC-4182, a novel immune-stimulating antibody conjugate (ISAC) targeting claudin 18.2 for gastric and gastroesophageal cancers, with init…
